DeepMed Research

Atridia Pty Ltd.

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Phase 1

Not yet recruiting

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: HRS-5041 Single dose of HRS-5041 orally administered

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-16

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 25

Registration Number: NCT06830850

Locations: 🇦🇺
Icon Cancer Centre South Brisbane, Brisbane, Australia
🇦🇺
John Flynn Private Hospital, Brisbane, Australia
🇦🇺
Eastern Health (Box Hill Hospital), Melbourne, Australia

and more 8 locations

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Phase 1

Withdrawn

Conditions: HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors

Interventions: Drug: SHR-4602

First Posted Date: 2024-08-19

Last Posted Date: 2025-01-07

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 20

Registration Number: NCT06560138

Locations: 🇦🇺
Scientia Clinical Research Limited, Randwick, New South Wales, Australia
🇦🇺
Macquarie University, Sydney, New South Wales, Australia
🇦🇺
Icon Cancer Centre South Brisbane, Brisbane, Queensland, Australia

and more 2 locations

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: HRS-5041 dose level 1
Drug: HRS-5041 dose level 2

First Posted Date: 2024-08-19

Last Posted Date: 2025-03-18

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 24

Registration Number: NCT06559007

Locations: 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia

Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

Early Phase 1

Completed

Conditions: MRI

Interventions: Drug: HRS-9231or matching placebo

First Posted Date: 2024-07-25

Last Posted Date: 2024-12-06

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 20

Registration Number: NCT06519981

Locations: 🇦🇺
Linear Clinical research, Perth, Western Australia, Australia

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Phase 1

Active, not recruiting

Conditions: Alzheimer's Disease (AD)

Interventions: Drug: SHR-1707 injection
Drug: Placebo

First Posted Date: 2023-11-02

Last Posted Date: 2025-04-15

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 12

Registration Number: NCT06114745

Locations: 🇦🇺
Liverpool Hospital, Sydney, New South Wales, Australia
🇦🇺
Southern Neurology, Sydney, New South Wales, Australia
🇦🇺
Austin Health, Melbourne, Victoria, Australia

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Phase 1

Completed

Conditions: Inflammatory Bowel Disease

Interventions: Drug: HRS-7085 tablets
Drug: Placebo tablet

First Posted Date: 2022-12-06

Last Posted Date: 2023-04-21

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 16

Registration Number: NCT05638347

Locations: 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: SHR-1921

First Posted Date: 2022-10-26

Last Posted Date: 2024-06-25

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 9

Registration Number: NCT05594875

Locations: 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia
🇦🇺
Sydney South West Private Hospital, Sydney, New South Wales, Australia
🇦🇺
Macquarie Hospital, Sydney, New South Wales, Australia

and more 1 locations

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Phase 1

Completed

Conditions: Advanced Malignant Tumors

Interventions: Drug: SHR-2002 and SHR-1316

First Posted Date: 2021-10-19

Last Posted Date: 2024-06-04

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 19

Registration Number: NCT05082545

Locations: 🇦🇺
Icon Cancer Centre, Brisbane, Queensland, Australia
🇦🇺
Liverpool Hospital, Sydney, Australia
🇦🇺
Linear clinical research, Perth, Western Australia, Australia

and more 1 locations

A Trial of SHR-1703 in Healthy Subjects

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: SHR-1703
Drug: Placebo

First Posted Date: 2021-04-22

Last Posted Date: 2021-12-01

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 1

Registration Number: NCT04855591

Locations: 🇦🇺
Nucleus Network, Brisbane, Queensland, Australia

A Trial of SHR2285 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: SHR2285

First Posted Date: 2021-04-02

Last Posted Date: 2022-03-08

Lead Sponsor: Atridia Pty Ltd.

Target Recruit Count: 31

Registration Number: NCT04829305

Locations: 🇦🇺
Linear Clinical research, Perth, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy